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Introduction: Although the survival rates of hematological patients admitted to the ICU are improving, little is
known about the long-term outcome. Our objective was to identify factors related to long-term outcome in
hematological patients after ICU discharge.
Methods: A prospective, observational study was carried out in seven centers in Spain. From an initial sample of
161 hematological patients admitted to one of the participating ICUs during the study period, 62 were discharged
alive and followed for a median time of 23 (1 to 54) months. Univariate and multivariate analysis were performed
to identify the factors related to long term-survival. Finally, variables that influence the continuation of the
scheduled therapy for the hematological disease were studied.
Results: Mortality after ICU discharge was 61%, with a median survival of 18 (1 to 54) months. In the multivariate
analysis, an Eastern Cooperative Oncology Group score (ECOG) >2 at ICU discharge (Hazard ratio 11.15
(4.626 to 26.872)), relapse of the hematological disease (Hazard ratio 9.738 (3.804 to 24.93)) and discontinuation
of the planned treatment for the hematological disease (Hazard ratio 4.349 (1.286 to 14.705)) were independently
related to mortality. Absence of stem cell transplantation, high ECOG and high Acute Physiology and Chronic
Health Evaluation II (APACHE II) scores decreased the probability of receiving the planned therapy for the
hematological malignancy.
Conclusions: Both ICU care and post-ICU management determine the long-term outcome of hematological
patients who are discharged alive from the ICU.Introduction
Hematological patients admitted into an ICU experience
high mortality rates. In response to this clinical problem,
research has helped to identify prognostic factors related
to intra-ICU and intra-hospital mortality. The result has
been an improvement in the outcome over the last decade
[1] as a consequence of a number of factors, including
implementation of non-invasive mechanical ventilation
[2], earlier intervention in septic shock [3] and better
management of specific complications (such as tumor* Correspondence: Teresa.bernal@sespa.princast.es
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reproduction in any medium, provided the orlysis syndrome) [4]. As most of the research has focused
on intra-ICU or intra-hospital mortality, information
regarding survival is limited to this period. More recently,
some groups have extended the follow-up period to 6 to
12 months after the patients have been discharged from
the ICU [5-10], but data regarding long-term survival
(more than one year after ICU discharge) are scarce. This
raises a concern about the validity of the classical pre-
dictive factors for intra-ICU or in-hospital mortality in
predicting long-term survival. For instance, the need for
mechanical ventilation is a well-known risk factor for
death in the ICU, but its impact in long-term survival is
largely unknown.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Patients included in the EMEHU study and subpopulation
included in the present study.
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eral condition of the patients at ICU discharge, including
nutritional, neuromuscular and cognitive status. These
factors, which are amenable to intervention and may
impact the long-term survival and quality of life in unse-
lected ICU patients, would be also relevant in a fragile
population such as those with hematological malignan-
cies. In addition, factors that determine the feasibility of
subsequent chemotherapy cycles after ICU discharge
and their impact in the long-term control of neoplastic
disease have not been studied.
Here we report on long-term outcome in a population
of hematological patients who survived ICU admission,
and analyze the clinical factors influencing survival. We
hypothesized that both intra-ICU and post-ICU variables
could determine the suitability of a patient for receiving
additional therapies, therefore determining the long-
term outcome of this population. To test this hypothesis,
we studied classical prognostic factors (such as mechan-
ical ventilation, organ failure and neutropenia), as well
as those related to the underlying disease and its evolu-
tion. In particular, we have analyzed the applicability of
chemotherapy after ICU discharge and its relevance to
hematological relapse and survival.
Methods
The Estudio Multicéntrico del Enfermo Hematológico en
UCI (EMEHU) study included all the hematological
patients (including those with neoplastic or non-
neoplastic disease), admitted due to medical or surgical
reasons to one of 34 ICUs in Spain during the June 2007
to September 2008 period [11]. From the 450 patients
included in the EMEHU database, 215 were discharged
alive. Among these, 67 patients were discharged from
one of the seven units participating in this sub-study.
Patients discharged for palliative care were not included
in the study. This resulted in a final sample of 62 ICU
survivors, which constitutes the object of this investiga-
tion (Figure 1). To exclude selection bias a comparison
was made between the patients included in the study
and those from the non-participating centers. There
were no differences in age, gender, hematological diag-
nosis, staging of the disease, percentage of transplanted
patients, acute physiology and chronic health evalu-
ation (APACHE)-II score at ICU admission or mortality
(data not shown).
The study was approved by local ethics committees
(see Acknowledgements) and written informed consent
was obtained for each participant.
Data collection
The EMEHU database included data on demographics,
hematological disease, diagnosis at ICU admission, se-
verity scores, treatments, infections and complicationsduring the ICU stay. Neutropenia was defined as an
absolute neutrophil count below 0.5 × 109 L-1 [12].
During the follow-up period after ICU discharge, data
on the Eastern Cooperative Oncology Group (ECOG)
score [13], relapse and treatment for the hematological
disease were collected. According to the compliance
with the pre-planned treatment for each hematological
disease, four groups of patients were predefined: 1) those
who did not require additional treatment (that is, patients
in complete remission or transplanted patients without
planned maintenance treatment); 2) patients who required
and received full-dose treatment; 3) patients who required
treatment and received it with modifications (reduced
doses or delays); and 4) Patients who required treatment
but did not receive it: for these patients the reasons for
the changes in the therapeutic plan were recorded.
Statistical analysis
Normality of all variables was studied using the
Kolgomorov-Smirnov test. Data are expressed as
mean ± SD or median (range) for variables with or
without a normal distribution respectively. Univariate
comparisons between survivors and non-survivors
after ICU discharge were performed using the Student
t-test, Mann–Whitney U-test or chi-square test. Those
variables with a P-value lower than 0.05 for the difference
Table 1 Characteristics of the study population
Number of patients (%)
or mean ± SD
Comorbidities
Coronary disease 5 (8)
Arterial hypertension 18 (29)
Diabetes 18 (29)
COPD 5 (8)
AIDS 2 (3)
Hepatic disease 3 (5)
Chronic renal failure 3 (5)
Non-hematologic cancer 4 (6)
Smoking 11 (18)
Tuberculosis 1 (2)
Hematological diagnosis
Acute myeloid leukemia/ myelodysplastic
syndrome
23 (38)
Acute lymphoid leukemia 4 (6)
Chronic myeloproliferative neoplasms 3 (5)
Chronic lymphocytic leukemia 5 (8)
Multiple myeloma 7 (11)
Hodgkin lymphoma 4 (6)
Non-Hodgkin lymphoma 11 (18)
Other 5 (8)
Timing of hematological diagnosis
Previous to hospital admission 39 (63)
During the current hospital admission 18 (29)
In ICU 5 (8)
Stage of disease at ICU admissiona
Remission-induction 26 (44)
Remission 19 (30)
Relapse 16 (26)
Stem cell transplant 11 (17)
APACHE II score (mean ± SD) 22 ± 7
Diagnosis at ICU admission
Acute respiratory failure 27 (44)
Sepsis 22 (35)
Cardiac failure 3 (5)
Cardiac arrest 1 (2)
Shock 16 (27)
Coma 2 (3)
Miscellaneous 6 (9)
aOne patient with paroxysmal nocturnal hemoglobinuria cannot be included
in this classification. COPD, chronic obstructive pulmonary disease; APACHE,
acute physiology and chronic health evaluation.
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order to deal with time-dependent variables (that is,
relapse), we used an extended Cox regression model.
Hazard ratios (HR) with 95% confidence intervals were
computed. A P-value lower than 0.05 was considered
significant in this multivariate analysis. To evaluate the
accuracy of the model over time, area under the incident/
dynamic receiver operating characteristic (ROC) curve
(AUC) was computed [14].
The four groups of patients resulting from the previ-
ously described classification based on the compliance
with the pre-planned treatment were compared using
one-way analysis of variance (ANOVA), Kruskal-Wallis
ANOVA or chi-square test, as appropriate. In order to
look for optimal classification criteria, significant variables
were included in a decision-tree analysis. In particular, the
chi-square automated interaction decision (CHAID) algo-
rithm was used, and variables with a P-value lower than
0.05 were considered significant.
Results
General characteristics of the sample
During the study period, the seven participating hospi-
tals admitted 161 patients. Sixty-two patients (39%) were
discharged alive from the ICU and were analyzed. There
were 36 male (59%) and 26 female (41%) patients. Age
was 53 ± 16 (mean ± SD) years. The most frequent under-
lying disease was acute leukemia (38% of the patients)
followed by lymphoma (24%). Most of the patients
with acute leukemia were receiving remission-induction
chemotherapy prior to ICU admission. Patients were
transferred to the ICU from the emergency department in
18 cases (29%) or from the hospital ward in 44 cases
(71%). The most common cause of ICU admission was
acute respiratory failure (44% of the patients) followed by
sepsis (35%) or shock (27%). There was only one surgical
patient (with laparotomy due to perforated typhlitis), all
the others being admitted due to medical reasons. All
these characteristics of the study population are summa-
rized in Table 1.
Patients were followed for a median time of 23 months
(range 1 to 54). Thirty-seven patients (59%) died after
ICU discharge, with a median overall survival of 18
months (range 1 to 54). Median follow-up time for
survivors was 43 months (11 to 54). Figure 2 shows the
survival curve for the study population.
Risk factors for mortality after ICU discharge
First, a univariate analysis comparing survivors and non-
survivors after ICU discharge was performed (Table 2).
There were no differences in age or sex between these
groups. Among the comorbid conditions, only a diagnosis
of arterial hypertension was related to mortality. Regard-
ing the hematological disease, there were no significantdifferences in mortality rates according to the main
diagnosis, although there was a non-significant trend to-
wards lower mortality rates in patients with lymphoma
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Figure 2 Overall survival of the whole population after ICU
discharge (continuous black line) with 95% confidence intervals
(dotted gray lines).
Table 2 Results of the univariate analysis studying the
differences in variables collected before ICU discharge
between long-term survivors and non-survivors
Alive Dead P-value
N = 26 N = 36
Age, years, mean ± SD 51 ± 14 55 ± 18 0.27
Gender, male/female 15/11 21/15 0.96
Hematological diagnosis 0.08
Acute leukemia/MDS 10 17
cMPN 0 3
CLL 2 3
Multiple myeloma 2 5
Lymphoma 11 4
Other 1 4
Phase of underlying diseasea 0.95
Remission-induction 11 15
Remission 8 11
Relapse 6 10
Arterial hypertension 0.04
Yes 4 14
No 22 22
Stem cell transplant 5 6 0.75
Neutropenia
Intra-ICU 12 28 0.02
Pre-ICU 8 22 0.03
Thrombopenia previous to ICU 15 28 0.09
Diagnosis at ICU admission:
Sepsis 10 12 0.67
Cardiac failure/infarction 0 3 0.26
Respiratory failure 13 15 0.69
Shock 4 11 0.23
Miscellaneous 6 2 0.06
APACHE- II score, mean ± SD 20.6 ±7.2 22 ± 6.7 0.42
Length of MV, days, median (range) 1 (0 to 42) 1 (0 to 62) 0.75
Length of NIMV, days, median (range) 0 (0 to 12) 0 (0 to 12) 0.60
Length of pre-ICU, days,
median (range)
5 (0 to 66) 3 (0 to 26) 0.43
Length of ICU stay, days,
median (range)
5 (1 to 58) 7 (1 to 68) 0.54
ECOG score at ICU discharge 0.001
0 to 2 25 22
3 to 4 1 14
Data are shown as number, mean ± standard deviation (SD) or median (range)
for normally and non-normally distributed variables, respectively. MDS,
myelodysplastic syndrome; cMPN, chronic myeloproliferative neoplasms; CLL,
chronic lymphocytic leukemia; APACHE, acute physiology and chronic health
evaluation; MV, mechanical ventilation; NIMV, non-invasive mechanical
ventilation; ECOG, Eastern Cooperative Oncology Group. aOne patient with
paroxysmal nocturnal hemoglobinuria cannot be included in this classification.
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disease, referral site of the patient (emergency room or
hospital ward) or history of stem-cell transplantation were
not related to survival. Presence of neutropenia before or
during the ICU stay was associated with a poor outcome.
In fact, both variables were closely correlated. Therefore,
we only considered neutropenia during the ICU stay
(HR 2,024, 95% CI 1.042, 3.937) for inclusion in the
multivariate analysis.
Among the data collected during the ICU stay, there
were no differences between survivors and non-survivors
in causes of admission, APACHE-II score, days of mech-
anical ventilation (either invasive or non-invasive) or com-
plications during this period (data not shown). However, a
high ECOG score at ICU discharge was significantly
related to mortality (HR 7.28, 95% CI 3.572 to 14.850, for
ECOG scores 3 to 4).
Finally, variables collected after ICU discharge were
analyzed. There were significant differences in the
relapse of the hematological disease (2 survivors versus
14 non-survivors respectively, chi-square test, P = 0.007).
Compliance with treatment for the hematological disease
also yielded statistically significant differences between
survivors and non-survivors: Only 5 out of 26 survivors
did not follow the previously planned therapeutic sched-
ule, in contrast to 18 out of 36 among non-survivors
(chi-square test, P = 0.02).
The five variables with a P-value lower than 0.05 were
included in a multivariate model (Table 3 and Figure 3).
In this analysis, relapse (Figure 3A), ECOG score at ICU
discharge (Figure 3B) and compliance with the sched-
uled treatment for the hematological disease (Figure 3C)
were significantly related to post-ICU mortality. The
Table 3 Multivariate analysis for survival
Hazard ratio 95% Confidence
interval
ECOG score > 2 at ICU discharge 11.150 4.626, 26.872
Relapse after ICU discharge 9.738 3.804, 24.93
Compliance with therapy
Finished treatment pre-ICU 1
Full treatment 1.075 0.319, 3.622
Dose reduction or delay 2.172 0.629, 7.501
No treatment 4.349 1.286, 14.705
ECOG, Eastern Cooperative Oncology Group.
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estimation of the AUC (Figure 3D). As shown, accuracy
was good immediately after ICU discharge (AUC 0.90)
and decreased to 0.77, 0,74 and 0.72 after one, two and
three years, respectively.
Therapeutic strategies after ICU discharge
Considering the impact of post-ICU treatment on survival
we analyzed factors that determined the probability of pa-
tients to receive pre-planned treatment for hematological
disease. Among the 62 studied patients, 15 did not need0 500 1000 1500
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treatment after ICU discharge, 12 patients received treat-
ment with dose reductions or delays (4 due to infection
and the remainder due to a medical decision) and 11 pa-
tients did not receive treatment for their hematological
disease (all due to a medical decision).
The differences among these groups were studied
using a decision-tree analysis. The three variables that
yielded significant differences were stem-cell transplant,
ECOG score at ICU discharge and APACHE-II score
(Figure 4). As expected, most transplanted patients did
not require more treatment after ICU discharge. How-
ever, patients with ECOG score >2 at ICU discharge,
and specifically those with an APACHE-II score above
21, received treatment with dose reductions or delays, or
discontinued the treatment more frequently.
Discussion
In this work we have analyzed the evolution of a cohort
of hematological patients after an ICU stay in order to
identify the factors related to long-term survival after
ICU discharge. Although the sample size of our study
could result in low statistical power, the robust statistical
analysis used, including univariate and multivariate
analysis, and restrictive cut-off points, have helped to
identify some relevant variables related to long-term
outcome. In this sense, an ECOG score >2 at ICU
discharge, the relapse of the hematological neoplasm
and the absence of compliance with the scheduled
therapy for the underlying disease after ICU discharge
predicted worse survival in this cohort. However, it must
be recognized that other variables may have not been
detected due to the sample size. In this sense, larger
studies will be required to validate our findings.
The need for data on long-term survival of hemato-
logical patients after ICU discharge has been recently
highlighted due to their increased acceptance in ICUs
[15], improvements in survival [1] and awareness of
resource consumption [16,17]. Our work presents dataStem cell
transplantation
Corrected p=0.007 
ECOG at
ICU discharge
Corrected p=0.01
No
Yes
No treatment needed
Treatment without changes
Treatment with delay/dose reduction
Treatment needed but not received
15 24 12 11
8 21 12 10
7 3 0 1
N
%
N
%
N
%
Figure 4 Decision-tree analysis showing the variables that significantly
acute physiology and chronic health evaluation score; ECOG, Eastern Cooperaafter a median follow-up time of 23 months, with 59%
mortality and a median survival of 18 months.
As most of the previously published studies dealing
with critically ill hematological patients are limited to
a follow-up period of 6 to 12 months [5-9,18], our
results are difficult to compare. In spite of this limita-
tion, high mortality rates after ICU discharge have
been uniformly described. This high number of deaths
must be added to the high ICU mortality of this
population (about 40 to 50% in the published litera-
ture [5-8,10] and 61% in our series). Nonetheless,
these findings were expected, as both an ICU stay
[19] and a diagnosis of a hematological neoplasm are
risk factors for death in the general population. More-
over, the most prevalent hematological diagnosis in
our cohort was acute leukemia during the induction
phase, a condition with high risk of infections and
death [20]. Due to the diagnostic heterogeneity of our
sample we cannot properly assess how the ICU stay
modifies the course of these diseases. With this limi-
tation in mind, we can compare our survival rates
with an unselected population of patients with acute
myeloid leukemia [21]. Our data show one-year mor-
tality higher than the 10 to 15% reported for the un-
selected population. However, long-term survival in
our study was about 40%, which is not very different
from the 50% reported for the whole cohort of pa-
tients with leukemia. The impact of an ICU stay in
the course of specific diseases should be addressed in
future studies.
The three predictive factors for survival in our study were
ECOG score at ICU discharge, relapse of hematological
disease and adherence to the planned therapy after
discharge. The ECOG score is a simple and easily applic-
able test that reflects the patient's response to the tumor
and quantifies the performance status of the subject. It
has demonstrated a prognostic value in virtually all
hematological neoplasms, independently of other clinical
and biological variables [22-25]. In the context of this2 
APACHE-II
Corrected p=0.050 3-4
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discriminated among the different therapeutic groups. APACHE-II,
tive Oncology Group score.
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intensive therapies required during the ICU stay may have
impact on the final ECOG score at ICU discharge.
Recently in a large cohort, poor performance status has
been demonstrated to be related to an increased risk of
intra-hospital death [10]. The second prognostic factor for
survival is relapse of underlying disease. This is not a
surprising result, considering that relapse confers a kind
of resistance to chemotherapy that is exceptionally
difficult to overcome except with aggressive therapies, like
stem-cell transplantation [26]. Finally, discontinuation of
the scheduled treatment for the hematological disease is
the third factor related to a poor outcome. This risk is
partially avoided when treatment is given, even with dose
reductions or delays.
Due to the relevance of this last factor, which has not
been explored previously, we focused on the variables
that could predict the adherence to the subsequent
hematological treatment. The decision-tree analysis
allows us to identify the most relevant parameters that
determine allocation to one group. The first variable that
determined the probability of treatment continuation
was stem-cell transplantation. As expected, patients after
stem-cell transplantation or those in complete remission
do not need further treatment for their disease, and
show a good prognosis after ICU discharge. Conversely,
those in the remission-induction phase or those with
relapse usually need additional treatments. It must be
noted that up to 50% of the patients in the remission-
induction phase do not receive full treatment after ICU
discharge. In these patients, the ECOG score appears
again as a critical factor that discriminates among groups
with different probabilities of receiving a complete chemo-
therapy treatment. According to our previous discussion,
patients with an ECOG score >2 at ICU discharge have a
substantially decreased functional reserve that hampers
their capacity to tolerate an aggressive treatment, such as
chemotherapy. This finding highlights the critical import-
ance of strategies aimed at minimizing the negative impact
of the ICU stay and preserving the patient's status [27].
Finally, the APACHE-II allows further discrimination
among the patients with high ECOG scores. A high
APACHE-II score decreased the probability of continu-
ation of therapy once the patient has been discharged
from the ICU. It has been demonstrated that early ICU
admission improves the outcome in this population
[10,28]. The admission before the development of multiple
organ dysfunction could be related to lower APACHE-II
scores and a better compliance with the treatment after
ICU discharge, thus improving the long-term outcome.
However, our data do not allow identification of other
factors that may have special relevance, such as specific
organ failure responsible for the medical reasons behind
the changes in the therapeutic plan.Collectively our study suggests that management of
critical hematological patients goes beyond the ICU and
represents a challenge for both hematologists and inten-
sivists: once a hematological patient is admitted to the
ICU, physicians should consider the need to follow the
therapeutic plan and not only the immediate risk of
death. Previous studies have demonstrated that when
needed, continuation of the chemotherapeutic regimen
after ICU admission could improve the outcome of these
patients [29]. Our results extend this observation, and
suggest that an active therapeutic strategy must be
taken after ICU discharge. If this goal cannot be ac-
complished, the ICU stay could be an exercise of
futility due to the high risk of death after discharge.
These findings should be taken into account when
considering readmission of one of these patients, due
to the poor outcome of those discharged alive but
unable to continue their treatment.Conclusions
Our results show that outcome of hematological patients
who are discharged alive from the ICU depends on their
functional status and the adherence to the planned
therapy for their disease. Moreover, these two factors are
closely related. These findings illustrate the relevance of
strategies to reduce the consequences of an ICU stay
and add new parameters to consider in the management
of this fragile population.Key messages
 Performance status, relapse of the hematological
disease and continuation of the scheduled
treatment for the hematological disease are the key
factors that determine long-term survival of
hematological
patients after an ICU stay.
 The ability to continue the planned treatment
for the hematological disease depends on
performance status and APACHE-II score.
Patients who have completed the stem-cell
transplant procedure or do not need more
treatment have a good outcome.
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